caa a22 4500 469073977 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741148 doi (NATIONALLICENCE)springer-10.1007/BF01741148 Tumor necrosis factor α modifies resistance to interferon α in vivo: First clinical data [Elektronische Daten] [Thomas Moritz, Otto Kloke, Marianne Nagel-Hiemke, Gerd Kummer, Ursula Wandl, Bertram Opalka, Birgit Plappert, Joachim Kempeni, Siegfried Seeber, Norbert Niederle] Summary: Patients with Philadelphia-positive chronic-phase chronic myelogenous leukemia (CML) resistant to interferon (IFN) α were treated in a phase I/II study with recombinant human tumor necrosis factor α to overcome IFNα resistance. Doses of 40, 80, 120 or 160 µg/m2 TNFα were given as 2-h infusions on 5 consecutive days every 3 weeks. IFNα (4 × 106 IU/m2 s.c., daily) treatment was continued. Six patients were treated, completing 1-24 (median, 12) treatment cycles. Five of the six patients achieved partial hematological remission, while the remaining patient had to stop treatment because of WHO grade 4 thrombocytopenia following the first TNFα cycle. No complete hematologic remission or cytogenetic improvement was seen. Side-effects were similar to those described for both substances alone. Maximum tolerable TNF doses usually varied between 80 µg/m2 and 160 µg/m2. To examine possible pathways of TNF activity in these patients, interferon receptor status and (2′-5′)-oligoadenylate synthetase levels were examined in peripheral blood mononuclear cells. Both parameters remained unchanged during TNFα treatment. These preliminary data point to significant clinical efficacy of additionally applyed TNFα in IFNα-resistant CML patients. Springer-Verlag, 1992 Tumor necrosis factor nationallicence Interferon α nationallicence Moritz Thomas Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Kloke Otto Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Nagel-Hiemke Marianne Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Kummer Gerd Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Wandl Ursula Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Opalka Bertram Institut für Molekularbiologie, University of Essen, Germany aut Plappert Birgit Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Kempeni Joachim Knoll AG, Ludwigshafen, Germany aut Seeber Siegfried Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut Niederle Norbert Innere Klinik III, Städtisches Krankenhaus, Leverkusen, Germany aut Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 342-346 0340-7004 35:5<342 1992 35 262 https://doi.org/10.1007/BF01741148 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741148 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Moritz Thomas Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Kloke Otto Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Nagel-Hiemke Marianne Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Kummer Gerd Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Wandl Ursula Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Opalka Bertram Institut für Molekularbiologie, University of Essen, Germany aut NATIONALLICENCE 700 1- Plappert Birgit Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Kempeni Joachim Knoll AG, Ludwigshafen, Germany aut NATIONALLICENCE 700 1- Seeber Siegfried Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany aut NATIONALLICENCE 700 1- Niederle Norbert Innere Klinik III, Städtisches Krankenhaus, Leverkusen, Germany aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 342-346 0340-7004 35:5<342 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer